CONTROLLED RELEASE OF BIOLOGICALLY ACTIVE COMPOUNDS
First Claim
Patent Images
1. A biodegradable polyester of formula III, VI, or XI, or a biodegradable polyamide ester of formula VIII or IX, or a pharmaceutically acceptable salt thereof:
- wherein the polyester of formula III is formed by condensation polymerization of monomers of formula I and II;
wherein the polyester of formula IV is formed by condensation polymerization of monomers of formula IV and V;
wherein the polyamide ester of formula VIII is formed by condensation polymerization of monomers of formula Va and VII;
wherein the polyamide ester of formula IX is formed by condensation polymerization of monomers of formula I and VII;
wherein the polyester of formula XI is formed by self condensation polymerization of a monomer of formula X;
wherein;
m, n, o, p, and q are each independently an integer from about 5 to about 1000;
R1, R5, R9, and R13 are each independently the remaining portion of a biologically active compound;
R2, R8, and R10 are each independently the remaining portion of a biologically active compound or non-biologically active compound;
R3, R4, R6, R7, R1, R12, and R13 are each independently selected from Cl, F, Br, and I;
X, X1 and X2 are independently at each occurrence —
OC(═
O)CH2—
(inverse glycolic acid moiety), —
OC(═
O)CH(CH3)—
(inverse lactic acid moiety), —
OC(═
O)CH2OCH2CH2—
(inverse dioxanone acid moiety), —
OC(═
O)CH2CH2CH2CH2CH2—
(inverse caprolactone acid moiety), —
OC(═
O)(CH2)y—
, or —
OC(═
O)CH2(OCH2CH2)n—
;
Y, Y1, and Y2 are independently at each occurrence —
CH2C(═
O)O—
(glycolic acid moiety), —
CH(CH3)C(═
O)O—
(lactic acid moiety), —
CH2CH2OCH2C(═
O)O—
(dioxanone moiety), —
CH2CH2CH2CH2CH2C(═
O)O—
(caprolactone moiety), —
(CH2)yC(═
O)O—
, or —
(CH2CH2O)zCH2C(═
O)O—
;
each y and z is independently an integer from about 2 to about 24;
each a, b, c, and d is independently an integer from about 1 to about 6;
each e is independently an integer from about 1 to about 6; and
each f is independently an integer from about 0 to about 6.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to biodegradable polymers (e.g., polyesters and polyester amides) derived from functionalized biologically active compounds that can provide site specific delivery of bioactive compounds upon biodegradation in a controlled manner.
-
Citations
37 Claims
-
1. A biodegradable polyester of formula III, VI, or XI, or a biodegradable polyamide ester of formula VIII or IX, or a pharmaceutically acceptable salt thereof:
-
wherein the polyester of formula III is formed by condensation polymerization of monomers of formula I and II; wherein the polyester of formula IV is formed by condensation polymerization of monomers of formula IV and V; wherein the polyamide ester of formula VIII is formed by condensation polymerization of monomers of formula Va and VII; wherein the polyamide ester of formula IX is formed by condensation polymerization of monomers of formula I and VII; wherein the polyester of formula XI is formed by self condensation polymerization of a monomer of formula X; wherein; m, n, o, p, and q are each independently an integer from about 5 to about 1000; R1, R5, R9, and R13 are each independently the remaining portion of a biologically active compound; R2, R8, and R10 are each independently the remaining portion of a biologically active compound or non-biologically active compound; R3, R4, R6, R7, R1, R12, and R13 are each independently selected from Cl, F, Br, and I; X, X1 and X2 are independently at each occurrence —
OC(═
O)CH2—
(inverse glycolic acid moiety), —
OC(═
O)CH(CH3)—
(inverse lactic acid moiety), —
OC(═
O)CH2OCH2CH2—
(inverse dioxanone acid moiety), —
OC(═
O)CH2CH2CH2CH2CH2—
(inverse caprolactone acid moiety), —
OC(═
O)(CH2)y—
, or —
OC(═
O)CH2(OCH2CH2)n—
;Y, Y1, and Y2 are independently at each occurrence —
CH2C(═
O)O—
(glycolic acid moiety), —
CH(CH3)C(═
O)O—
(lactic acid moiety), —
CH2CH2OCH2C(═
O)O—
(dioxanone moiety), —
CH2CH2CH2CH2CH2C(═
O)O—
(caprolactone moiety), —
(CH2)yC(═
O)O—
, or —
(CH2CH2O)zCH2C(═
O)O—
;each y and z is independently an integer from about 2 to about 24; each a, b, c, and d is independently an integer from about 1 to about 6; each e is independently an integer from about 1 to about 6; and each f is independently an integer from about 0 to about 6. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)
-
-
3. A biodegradable polyester of claim 1 having formula VI or a pharmaceutically acceptable salt thereof:
-
4. A biodegradable polyamide ester of claim 1 having formula VIII or a pharmaceutically acceptable salt thereof:
-
5. A biodegradable polyamide ester of claim 1 having formula IX or a pharmaceutically acceptable salt thereof:
-
6. A biodegradable polyester of claim 1 having formula XI or a pharmaceutically acceptable salt thereof:
-
7. A polyester of claim 3, wherein the non-biologically active compound is a dicarboxylic compound selected from:
-
8. A polyester of claim 2, wherein the non-biologically active compound is a diamino compound selected from:
-
9. A polyamide ester of claim 4, wherein the non-biologically active compound is a diamino compound selected from:
-
10. A polyamide ester of claim 5, wherein the non-biologically active compound is a diamino compound selected from:
-
11. A biodegradable monomer according to claim 1, wherein the monomer is selected from formula I, II, IV, V, Va, VII and X.
-
12. A composition comprising at least two different polymers, wherein each polymer is independently a polyester or polyamide ester according to claim 1.
-
13. A cosmetic composition comprising a cosmetic ingredient and at least one polymer according to claim 1.
-
14. An implantable medical device comprising at least one polymer according to claim 1.
-
15. An implantable medical device of claim 14, wherein the polymer has been further polymerized with a lactone monomer selected from glycolide, lactide, ε
- -caprolactone, trimethylene carbonate, ether lactones, morpholinediones, and p-dioxanone.
-
16. An implantable medical device of claim 14, wherein the device is a stent.
-
17. An implantable medical device of claim 16, wherein the polymer has been further polymerized with a lactone monomer selected from glycolide, lactide, ε
- -caprolactone, trimethylene carbonate, ether lactones, morpholinediones, and p-dioxanone.
-
18. An implantable medical device of claim 14, wherein the device is a scaffold for tissue engineer comprising a porous structure for the attachment and proliferation of cells.
-
19. An implantable medical device of claim 18, wherein the polymer has been further polymerized with a lactone monomer selected from glycolide, lactide, ε
- -caprolactone, trimethylene carbonate, ether lactones, morpholinediones, and p-dioxanone.
-
20. A coating for a stent comprising at least one polymer according to claim 1.
-
21. A stent coating of claim 20, wherein the polymer has been further polymerized with a lactone monomer selected from glycolide, lactide, ε
- -caprolactone, trimethylene carbonate, ether lactones, morpholinediones, and p-dioxanone.
-
22. A drug delivery system comprising at least one polymer according to claim 1 physically admixed with a biologically or pharmacologically active agent.
-
23. A drug delivery system of claim 22, wherein the biologically or pharmacologically active agent is physically embedded or dispersed into the polymer and the polymer is in the form of a polymeric matrix.
-
24. A suture coating comprising at least one polymer according to claim 1.
-
25. A suture comprising at least one polymer according to claim 1.
-
26. An antimicrobial agent comprising at least one polymer according to claim 1.
-
27. A method for treating a disease in a patient, comprising administering to an animal in need of such therapy, an effective amount of at least one polymer according to claim 1.
-
28. A method for producing an analgesic effect in a patient comprising administering to an animal in need of such therapy, an effective amount of at least one polymer according to claim 1.
-
29. A method for treating cancer in a patient comprising administering to an animal in need of such therapy, an effective amount of at least one polymer according to claim 1.
-
30. A method for producing an anti-inflammatory effect in a patient comprising administering to an animal in need of such therapy, an effective amount of at least one polymer according to claim 1.
-
31. A method for producing an anti-bacterial effect in a patient comprising administering to an animal in need of such therapy, an effective amount of at least one polymer according to claim 1.
-
32. A method for producing an anti-fungal effect in a patient comprising administering to an animal in need of such therapy, an effective amount of at least one polymer according to claim 1.
-
33. A method for producing an immunosuppressive effect in a patient comprising administering to an animal in need of such therapy, an effective amount of at least one polymer according to claim 1.
-
34. A method for producing an anti-thrombotic effect in an patient comprising administering to an animal in need of such therapy, an effective amount of at least one polymer according to claim 1.
-
35. A method for treating psoriasis, inflammatory bowel disease, skin cancer, or a brain tumor in an patient, comprising administering to an animal in need of such therapy, an effective amount of at least one polymer according to claim 1.
-
36. A method for producing an anti-infective effect in a patient comprising administering to an animal in need of such therapy, an effective amount of at least one polymer according to claim 1.
-
37. A therapeutic method for treating pain in a patient comprising administering to an animal in need of such therapy, an effective amount of at least one polymer according to claim 1.
Specification